SML3568

C26-A6

≥98% (HPLC)

• Synonim(y): 5-chloro-2-methoxy-N-(2-methyl-[1,2,4]triazolo[1,5-a]pyridin-8-yl)benzenesulfonamide
• Wzór empiryczny (zapis Hilla): C₁₄H₁₃ClN₄O₃S
• Numer CAS: 1341030-00-9
• Masa cząsteczkowa: 352.80
• UNSPSC Code: 12352200
• NACRES: NA.21
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear (Warmed)
• storage temp.: 2-8°C
• SMILES string: O=S(NC1=CC=CN2N=C(C)N=C12)(C3=CC(Cl)=CC=C3OC)=O
• InChI key: HLRMNXITZQAUIH-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

A26-A6 is a MTDH-SND1 interaction blocker (IC50 = 2.4 μM by cell-free & 12.3 μM by cellular split-luc assay) that competes against metadherin (MTDH; AEG-1; LYRIC) for staphylococcal nuclease domain-containing 1 (SND1) binding, thereby preventing MTDH-SND1 complex from suppressing antitumor T cell responses. A26-A6 inhibits PyMT tumor sphere formation in cultures (IC50 <200 μM) in a MTDH- and SND1-dependent manner and exhibits in vivo efficacy against breast tumor growth and metastasis in mice in vivo (15 mg/kg/d i.v. 5d/wk), including the murine PyMT model, and human breast cancer xenografts (PDX, HCI-001, SCP28).

Metadherin-staphylococcal nuclease domain-containing 1 (MTDH-SND1) interaction inhibitor with anti-triple-negative breast cancer (TNBC) efficacy in vivo.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable